Siponimod (mayzent) in secondary progressive MS reduced EDSS ≥ 7.0 (requiring a wheelchair) by 40% (from the EXPAND randomized trial against placebo) (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.88; p = 0.009) onlinelibrary.wiley.com/doi/10.1111/...
Siponimod lowered the risk of wheelchair use in SPMS patients compared to placebo, especially in those with active disease. Time to wheelchair is a key metric for evaluating treatment in SPMS.
